RH
RHT.AU Resonance Health Ltd
- Market cap
- AUD 35.3M
- P/E
- -
- P/B
- 3.18x
- ROE
- 13.6%
- Dividend yield
- -
- Fundamental score
- 2.3/5
Ratios use the latest price and the fiscal year ending Jun 2026.
Is RHT.AU undervalued?
Graham numberThe Graham number of Resonance Health Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Resonance Health Ltd fundamental analysis
11 of 22 checks passedROE 1/2
Moderate return on equity (13.6%), between 10% and 20%.
ROA 1/1
Return on assets (8.1%) is above the industry median (-35.3%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 1/1
Earnings per share grew over the past 5 years.
Earnings Acceleration 1/1
Last year's EPS growth (182.2%) is above the 5-year average (19.3% a year).
Earnings Growth vs Industry 1/1
Last year's EPS growth (182.2%) is above the industry median (24.9%).
Revenue Growth 2/2
Revenue grew 52.9% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 2/2
Low debt to equity (34.3%), 40% or less.
Debt Trend 0/1
Debt to equity has risen over the past 5 years.
Debt Coverage 1/1
Operating cash flow covers 20% of total debt.
Interest Coverage 0/1
EBIT is 4.5x against interest expense, below 5x.
PE vs Market 0/1
PE is negative or not available.
PE vs Industry 0/1
PE is negative or not available.
PBV 1/1
Price to book (3.2x) is below the industry median (4.0x).
Graham Number 0/1
Graham number needs positive earnings and book value.
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Resonance Health Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Resonance Health Ltd
Resonance Health Limited, a healthcare technology and services company, designs, develops, manufactures, and commercializes software-as-medical devices (SaMD) in the Asia Pacific, North America, Europe, the Middle East, and Africa. It operates through SaMD, Resonance Clinical, and TrialsWest segments. The company offers FerriScan, a non-invasive MRI based solution for quantifying liver iron concentration (LIC); FerriSmart, an artificial intelligence (AI) solution for the aut…
Full company profileResonance Health Ltd financial statements
Resonance Health Ltd annual financial statements (AUD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 2.49M | 2.90M | 3.63M | 3.67M | 3.78M | 3.83M | 4.40M | 8.59M | 11.1M | 15.8M |
| Gross Profit | 2.49M | 2.90M | 3.63M | 3.67M | 3.78M | 3.83M | 4.40M | 8.59M | 11.1M | 14.8M |
| Operating Income | -622K | -261K | 867K | -1.18M | 188K | -1.77M | -1.62M | -879K | -1.93M | 1.53M |
| EBITDA | -425K | -81.5K | 1.11M | -612K | 708K | -1.34M | -828K | -382K | -619K | 2.48M |
| Net Income | -304K | 225K | 1.27M | -715K | 586K | -1.14M | -780K | 169K | -1.73M | 1.51M |
| EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Balance Sheet | ||||||||||
| Total Assets | 4.62M | 4.69M | 6.42M | 10.5M | 12.4M | 11.7M | 11.0M | 20.3M | 17.9M | 18.7M |
| Total Liabilities | 884K | 552K | 523K | 591K | 612K | 996K | 1.05M | 9.35M | 8.50M | 7.63M |
| Shareholders' Equity | 3.73M | 4.13M | 5.89M | 9.91M | 11.8M | 10.7M | 9.94M | 10.9M | 9.39M | 11.1M |
| Cash & Short-term Investments | 1.69M | 1.55M | 3.08M | 6.97M | 8.86M | 6.78M | 6.36M | 6.85M | 2.98M | 4.85M |
| Total Debt | - | - | - | 116K | 60.1K | 268K | 273K | 3.70M | 3.80M | 3.81M |
| Cash Flow | ||||||||||
| Operating Cash Flow | -282K | 378K | 1.62M | 1.31M | 1.17M | -1.46M | -157K | 1.39M | 1.25M | 2.88M |
| Capital Expenditure | 478K | 547K | 348K | 251K | 396K | 704K | 468K | 377K | 443K | 94.8K |
| Free Cash Flow | -760K | -169K | 1.27M | 1.06M | 773K | -1.42M | -625K | 1.01M | 805K | 2.79M |
| Ratios | ||||||||||
| ROE | -8.1% | 5.4% | 21.5% | -7.2% | 5.0% | -10.7% | -7.9% | 1.5% | -18.5% | 13.6% |
| ROA | -6.6% | 4.8% | 19.8% | -6.8% | 4.7% | -9.8% | -7.1% | 0.8% | -9.7% | 8.1% |
| Net Profit Margin | -12.2% | 7.8% | 35.0% | -19.5% | 15.5% | -29.8% | -17.7% | 2.0% | -15.7% | 9.6% |
| Debt to Equity | - | - | - | 0.01x | 0.01x | 0.03x | 0.03x | 0.34x | 0.40x | 0.34x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Resonance Health Ltd dividends
Resonance Health Ltd has not paid dividends in the last 10 fiscal years.
Last stock split: 1:10 on Oct 15, 2003.
Who owns Resonance Health Ltd
- Insiders 38.57%
- Institutions 0.00%
- Public & others 61.43%
- Shares outstanding 477M
- Free float 288M
Resonance Health Ltd company profile
- Company name
- Resonance Health Ltd
- Ticker
- RHT.AU
- ISIN
- AU000000RHT2
- Exchange
- Australian Securities Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Fiscal year end
- June
- Address
- 141 Burswood Road, Burswood, WA, Australia, 6100
- Phone
- 61 8 9286 5300
- Website
- resonancehealth.com
About Resonance Health Ltd
Resonance Health Limited, a healthcare technology and services company, designs, develops, manufactures, and commercializes software-as-medical devices (SaMD) in the Asia Pacific, North America, Europe, the Middle East, and Africa. It operates through SaMD, Resonance Clinical, and TrialsWest segments. The company offers FerriScan, a non-invasive MRI based solution for quantifying liver iron concentration (LIC); FerriSmart, an artificial intelligence (AI) solution for the automated real-time assessment of LIC; HepaFatScan, a non-invasive MRI-based solution for the assessment of liver-fat in liver tissue; HepaFatSmart, an AI-trained device for the automated real-time multi-metric measurement of liver-fat; LiverSmart, a non-invasive MRI-based multi-parametric device combining FerriSmart and HepaFatSmart into a consolidated report; and CardiacT2, a dual analysis service with FerriScan for assessing heart iron loading. It also provides phantoms comprising FerriScan, T1CMR, and T2CMR phantoms for the calibration of MRI machines. In addition, the company operates as an imaging contract research organization that provides comprehensive proposal and project management support, site set-up, imaging charter development, clinical reports, data transfer agreements, and compliance services for clinical trial sponsors. It serves clinicians for the management of human diseases; and pharmaceutical and therapeutic companies for clinical trials. Resonance Health Limited was incorporated in 1987 and is headquartered in Burswood, Australia.
Resonance Health Ltd management
6- Mr. Andrew Duncan Harrison BCom (Hons), MAICDCEO, MD & Director · born 1971
- Mr. Benjamin CarruthersChief Financial Officer
- Mr. Mitchell M. Wells B.Com., B.Comm, L.L.B.Company Secretary & Non Executive Director · born 1975
- Mr. Gavin PintoChief Technology Officer
- Ms. Narelle MounseyGeneral Manager of People & Culture
- Dr. Wenjie Pang Ph.D.Chief Scientific Officer ? Imaging & AI